D11 - The Incredible Incretins: Unlocking New Frontiers with Incretin-Based Therapies

Sunday, August 10, 2025

11:00 AM - 11:45 AM MST

CE/CME Hours: .75 CE

Pharmacology Hours: .75 CE
Universal Activity Number (Live): JA4008258-0000-25-154-L01-P
University Activity Number (Home): JA4008258-0000-25-222-H01-P

The session will delve into potential therapeutic advantages of incretin-based therapies in a variety of conditions, including but not limited to, Alzheimer's disease, sleep apnea, substance use disorder, depression, Parkinson's disease, psoriasis, and polycystic ovary syndrome (PCOS). We will discuss emerging evidence, promising clinical trials, and mechanisms that might explain these benefits. The presenters will examine the latest research on how incretin-based therapies can improve outcomes for patients with heart failure, metabolic dysfunction-associated steatotic liver disease, and chronic kidney disease. Attendees will gain an understanding of opportunities to integrate incretin-based therapies into treatment plans for individuals with conditions beyond diabetes and obesity.

Disclosure(s):

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP: Abbott: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Terminated, April 21, 2023)

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP: Abbott: Speakers' Bureau (Ongoing); Dexcom: Speakers' Bureau (Ongoing); Insulet: Speakers' Bureau (Ongoing); Lilly: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing); Sequel: Consultant / Advisory Board (Ongoing)

Allyson S. Hughes, PhD: No financial relationships to disclose

Primary Presenter(s)

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP (she/her/hers)

Professor, Pharmacy Practice, PGY2 Ambulatory Care Residency Program Director, Clinical Pharmacist
Midwestern University and Northwestern Medicine

Disclosure(s): Abbott: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Terminated, April 21, 2023)

Co-Presenter(s)

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP (she/her/hers)

Director, Education and Training in Diabetes Technology
Cleveland Clinic

Disclosure(s): Abbott: Speakers' Bureau (Ongoing); Dexcom: Speakers' Bureau (Ongoing); Insulet: Speakers' Bureau (Ongoing); Lilly: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing); Sequel: Consultant / Advisory Board (Ongoing)

Session Host(s)

Baleana Watts-McGilberry, BS, RDN, LDN, CDCES (she/her/hers)

Nutrition and Diabetes Consultant
Baleana Watts-McGilberry Consulting